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Abstract: To explore the effects of immunotherapy in the International Society of Paediatric Oncology
Europe Neuroblastoma Group SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1 trial), two cohorts
were studied: one prior to and one after the introduction of dinutuximab beta. All patients received
standard induction and high-dose therapy (HDT) with autologous stem cell rescue (ASCR); the local
control comprised surgery and radiotherapy to the primary tumour site, followed by isotretinoin. A
landmark timepoint of 109 days, resulting from the median time between ASCR and initiation of
immunotherapy, was used to define patients’ eligibility in the pre-immunotherapy analysis cohort.
Median follow-up was 5.8 years (inter-quartile range (IQR): 4.2–8.2 years) for 844 eligible patients
balanced for risk factors, such as age, sex, stage 4, MYCN amplification and response prior to HDT.
The five-year event-free and overall survival (95% confidence interval (CI) of 466 patients not receiving
immunotherapy was 42% (38–47%) and 50% (46–55%) but was 57% (51–62%) and 64% (59–69%)
for 378 patients receiving immunotherapy (p < 0.001). A multivariate analysis identified absence
of immunotherapy (p = 0.0002, hazard ratio (HR) 1.573); type of HDT (p = 0.0029, HR 1.431); less
than complete response prior to maintenance therapy (p = 0.0043, HR 1.494) and >1 metastatic
compartment at diagnosis (p < 0.001, HR 2.665) as risk factors for relapse or progression. Results
suggest an important role for dinutuximab beta-based immunotherapy within the treatment concepts
applied in HR-NBL1/SIOPEN.
Keywords: high-risk neuroblastoma; immunotherapy; dinutuximab beta
1. Introduction
High-risk neuroblastoma defined by metastatic diseases over the age of 12 or 18 months [1] and
MYCN amplification at any age remain associated with long-term survival rates of only 40% [2,3].
Treatment approaches comprise intensive induction [4,5], consolidation with high-dose chemotherapy
(HDT) and autologous stem cell rescue (ASCR) [3,6], and isotretinoin as maintenance therapy.
As the disialoganglioside GD2 is expressed on the majority of neuroblastoma cells, with minimal
expression on normal cells, it is a suitable target for immunotherapy [7]. Therefore, human/mouse
chimeric anti-GD2 antibody ch14.18, dinutuximab, produced in SP2/0 cells was developed and
investigated in clinical trials [8]. In Europe, ch14.18 was re-cloned in Chinese hamster ovarian
(CHO) cells (dinutuximab beta) [9] for clinical trials of International Society of Paediatric Oncology
Europe Neuroblastoma Group SIOPEN. The tolerability and activity of dinutuximab beta was first
evaluated in a dose schedule of 20 mg/m2 given on five consecutive days by an 8 h infusion [10].
In 2006, SIOPEN opened a randomised trial to compare dinutuximab beta and isotretinoin with
isotretinoin alone in patients with high-risk neuroblastoma. However, in 2007, the results of the
Children’s Oncology Group (COG) ANBL0032 trial were communicated, followed by publication in
2010 [7], demonstrating that two-year event-free survival (EFS) and overall survival (OS) of patients
with high-risk neuroblastoma receiving dinutuximab and cytokines (granulocyte-macrophage colony
stimulating factor and interleukin-2), in addition to isotretinoin, were significantly higher by 20% and
11%, respectively [7], compared to those patients receiving isotretinoin alone. Therefore, continuation
of the SIOPEN randomised trial was believed to be no longer feasible nor considered ethical, and
the study design was modified to allow all patients to receive dinutuximab beta with or without
interleukin-2. The altered randomisation opened on 22 October 2009 to investigate the role of
subcutaneous interleukin-2 (sc-IL-2) with dinutuximab beta and assigned patients to dinutuximab
beta alone or with sc-IL-2 [11]. All patients received oral isotretinoin [12]. The trial showed that the
addition of sc-IL-2 to immunotherapy with dinutuximab beta, given as an 8 h infusion, did not improve
outcome but increased toxicity.
In this report, we aim to assess the contribution of dinutuximab beta-based immunotherapy to the
outcome of patients with high-risk neuroblastoma in the International Society of Paediatric Oncology
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Europe Neuroblastoma Group High-Risk Neuroblastoma 1 (HR-NBL1/SIOPEN) trial by investigating
the survival of patients in sequential eras with the same eligibility criteria treated with (immunotherapy
population (IP), 2009–2013) [12] or without immunotherapy (control population (CP), 2002–2009).
2. Results
2.1. Patient Characteristics
According to the inclusion criteria for the analysis, 844 patients enrolled in 146 SIOPEN member
hospitals/institutions in 19 countries were eligible (378 in the IP and 466 in the CP) (Figure 1). Median
follow-up was 5.8 years (inter-quartile range (IQR): 4.2 to 8.2 years). The median age of patients at
diagnosis was 2.9 years (IQR: 1.8. to 3.8).
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Figure 1. Flow chart for the analysis cohort. HDT (high-dose chemotherapy); BuMel (high-dose 
chemotherapy with busulfan and melphalan; CEM (high-dose chemotherapy with carboplatin, 
etoposide and melphalan); R1 (high-dose chemotherapy randomisation); R2 (immunotherapy 
randomisation) and IL-2 (interleukin-2). 
Both populations were balanced for sex, stage 4, MYCN amplification and response prior to HDT 
(Table 1). 
Table 1. Characteristics of the control and immunotherapy populations. N = number; % = percentage; 
MNA = MYCN amplification; no = not present and yes = present; MC = metastatic compartments; TVD 
= topotecan, vincristine and doxorubicin; HDT = high-dose chemotherapy; BuMel = high-dose 
chemotherapy with busulfan and melphalan; CEM = high-dose chemotherapy with carboplatin, 
etoposide and melphalan; NR = not reported; CR = complete remission; VGPR = very good partial 
remission; PR = partial remission; CME = complete macroscopic excision and IME = incomplete 
macroscopic excision. 
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2.2. Survival
The five-year EFS was 57% (95% CI: 51–62%) for IP, compared to 42% (95% CI: 38–47%) for CP
patients (p < 0.001) (Figure 2A). The five-year overall survival (OS) for the IP was 64% (95% CI: 59–69%),
compared to 50% (95% CI: 46-55%) for CP patients (Figure 2B).
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Table 1. Characteristics of the control and immunotherapy populations. N = number; % = percentage;
MNA = MYCN amplification; no = not present and yes = present; MC = metastatic compartments;
TVD = topotecan, vincristine and doxorubicin; HDT = high-dose chemotherapy; BuMel = high-dose
chemotherapy with busulfan and melphalan; CEM = high-dose chemotherapy with carboplatin,
etoposide and melphalan; NR = not reported; CR = complete remission; VGPR = very good partial
remission; PR = partial remission; CME = complete macroscopic excision and IME = incomplete
macroscopic excision.
Characteristics
Control Population ImmunotherapyPopulation
n % n %
Total number 466 378
Sex Female 180 39% 140 37%
Male 286 61% 238 63%
Age <1.5 years 64 13% 55 14%
1.5-<5
years 333 71% 254 67%
≥5 years 69 15% 69 18%
Median 2.70 2.87
Stage Localised 60 13% 32 8%
Stage 4 406 87% 339 90%
Stage 4s 0 0% 7 2%
MYCN Stage 4 MNA NR 27 6% 16 4%
MNA no 217 57% 197 61%
MNA yes 162 43% 126 39%
MC NR 23 5% 23 6%
0 60 14% 32 9%
1 70 16% 35 10%
2 136 31% 112 32%
3 120 27% 112 32%
>3 57 13% 64 18%
TVD given NR 23 5% 10 3%
No 391 88% 250 68%
Yes 52 12% 118 32%
Surgery CME 318 76% 261 75%
IME 101 24% 87 25%
Status prior HDT NR 25 5% 33 9%
CR 174 39% 116 34%
VGPR 159 36% 149 43%
PR 108 24% 80 23%
HDT BuMel 257 55% 348 92%
CEM 209 45% 30 8%
Status prior Maintenance NR 58 12% 17 4%
CR 258 63% 210 58%
VGPR 93 23% 99 27%
PR 57 14% 52 14%
The cumulative incidence of relapse/progression (CIR) at five years was 41% (95% CI: 37–47%) for
the IP and 57% (95% CI: 53–61%) for the CP patients (p < 0.001). At the last follow-up, 153 patients of
the IP had an event versus 272 of CP patients. The cumulative incidence of non-relapse mortality was
2% (95% CI: 1–4%) in the IP and 1% (95% CI < 1–2%) in the CP (Figure 2C).
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2.3. Influence of Risk Factors
Disease status prior to maintenance therapy was available in 769/844 (91%) patients (Table 2).
Older age; stage 4; involvement of more than one metastatic compartment (MC); disease status prior to
maintenance therapy; addition of topotecan, vincristine and doxorubicin (TVD) and use of carboplatin,
etoposide and melphalan (CEM) as HDT were associated with lower EFS (Figure 3) in the population
analysed. Patients with lymph nodes as their only MC (five-year EFS 60% (95% CI: 36–78%)) had a
similar EFS as patients with other isolated metastatic sites (five-year EFS 60% (95% CI: 49–70%)).
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Table 2. Outcomes according to risk factors and subgroups. (2A) Event-free survival and (2B) overall survival. Pts (patients); 95% CI (95% confidence interval); p-
value (probability value for A: comparison according to risk factor and B: for interaction); MNA (MYCN amplification); - (not present) and + (present); MC (metastatic
compartments); TVD (topotecan, vincristine and doxorubicin); HDT (high-dose chemotherapy); BuMel (high-dose chemotherapy with busulfan and melphalan); CEM
(high-dose chemotherapy with carboplatin, etoposide and melphalan); CR (complete remission); VGPR (very good partial remission; PR (partial remission); CME
(complete macroscopic excision) and IME (incomplete macroscopic excision).
Characteristics Total Population Control Group Immunotherapy Group p-Value B
(A) Event Free Survival Events/Pts 5-years EFS (95% CI) p-value A Events/Pts 5-years EFS (95% CI) Events/Pts 5-years EFS (95% CI)
Total 844 Pts 466 Pts 378 Pts
Sex female 164/320 49 (44–55) 0.803 105/180 43 (36–50) 59/140 57 (49–65) 0.938
male 273/524 48 (44–52) 171/286 41 (36–47) 102/238 56 (49–62)
Age <1.5 years 48/119 60 (51–68) 0.007 27/64 59 (46–70) 21/55 61 (47–73) 0.161
1.5–<5 years 302/587 49 (44–53) 194/333 42 (37–47) 108/254 57 (50–63)
≥5 years 87/138 38 (30–47) 55/69 25 (16–36) 32/69 53 (40–64)
Stage Localised 25/92 72 (62–80) <0.001 14/60 76 (63–85) 11/32 66 (47–79) 0.007
Stage 4 410/745 45 (42–49) 262/406 37 (32–42) 148/339 56 (50–61)
Stage 4s 2/7 71 (26–92) – – 2/7 71 (26–92)
Stage 4 MNA no– 236/414 43 (38–48) 0.819 147/217 33 (27–39) 89/197 54 (47–61) 0.25
Stage 4 MNA yes+ 154/288 47 (41–53) 98/162 42 (34–49) 56/126 55 (45–63)
MC 0 25/92 72 (62–80) <0.001 14/60 67 (63–85) 11/32 66 (47–79) 0.025
1 43/105 60 (50–69) 34/70 54 (42–65) 9/35 71 (50–85)
2 136/248 46 (39–52) 85/136 39 (31–47) 51/112 55 (45–63)
3 134/232 43 (36–49) 89/120 27 (20–36) 45/112 60 (50–69)
>3 76/121 37 (28–46) 42/57 28 (17–40) 34/64 45 (32–57)
TVD no 322/641 50 (46–54) 0.024 225/391 44 (39–49) 97/250 61 (54–67) 0.732
yes 100/170 39 (32–47) 38/52 27 (16–39) 62/118 45 (34–55)
Surgery CME 288/578 50 (46–54) 0.123 183/318 43 (38–49) 105/260 59 (52–65) 0.946
IME 106/188 45 (38–52) 66/101 38 (29–48) 40/87 53 (42–63)
Status Prior HDT
CR 134/290 54 (48–59) 0.022 86/174 51 (43–58) 48/116 57 (47–66) 0.294
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Table 2. Cont.
VGPR 171/308 45 (39–51) 104/159 36 (29–44) 67/149 55 (46–63)
PR 104/188 45 (38–53) 70/108 38 (29–47) 34/80 57 (45–67)
Characteristics Total Population Control Group Immunotherapy Group p–value B
(A) Event Free Survival Events/Pts 5–years EFS (95% CI) p–value A Events/Pts 5–years EFS (95% CI) Events/Pts 5–years EFS (95% CI)
HDT BuMel 288/605 52 (48–56) <0.001 137/257 48 (41–54) 151/348 56 (50–61) 0.055
CEM 149/239 39 (33–45) 139/209 35 (29–42) 10/30 67 (47–80)
Status Prior Maintenance
CR 225/468 52 (48–47) 0.002 144/258 46 (39–52) 81/210 61 (53–67) 0.84
VGPR 98/192 50 (42–56) 55/93 43 (33–53) 43/99 56 (46–66)
PR 70/109 35 (26–44) 42/57 26 (15–33) 28/52 45 (32–58)
(B) Overall Survival Events/ Pts 5-year OS (95% CI) p-value A Events/Pts 5-year OS (95% CI) Events/Pts 5-year OS (95% CI)
Sex female 138/320 59 (53–64) 0.536 95/180 53 (45–60) 43/140 59 (53–64) 0.488
male 234/524 55 (50–59) 150/286 49 (43–55) 84/238 55 (50–59)
Age <1.5 years 45/119 62 (52–70) 0.445 26/64 61 (48–72) 19/55 62 (52–70) 0.409
1.5–<5 years 259/587 57 (53–61) 177/333 50 (45–55) 82/254 57 (53–61)
≥5 years 68/138 49 (40–58) 42/69 42 (30–54) 26/69 49 (40–58)
Stage localised 24/92 76 (66–83) 0.001 13/60 82 (69–89) 11/32 76 (66–83) 0.003
Stage 4 347/745 54 (50–57) 232/406 46 (41–51) 115/339 54 (50–57)
Stage 4s 0/7 83 (27–97) 0/0 1/7
Stage 4
MNA no- 193/414 53 (47–58) 0.235 129/217 43 (37–50) 64/197 53 (47–58) 0.150
Stage 4
MNA yes+ 137/288 54 (48–60) 88/162 49 (41–56) 49/126 54 (48–60)
MC 0 24/92 76 (66–83) <0.001 13/60 82 (69–89) 11/32 76 (66–83) 0.013
1 36/105 68 (58–76) 29/70 62 (50–73) 7/35 68 (58–76)
2 109/248 56 (50–62) 71/136 51 (42–59) 38/112 56 (50–62)
3 117/232 49 (42–56) 81/120 36 (27–44) 36/112 49 (42–56)
>3 70/121 43 (34–52) 41/57 32 (20–44) 29/64 43 (34–52)
TVD no 281/641 57 (53–61) 0.224 200/391 52 (47–57) 81/250 57 (53–61) 0.441
yes 78/170 52 (44–60) 34/52 36 (23–49) 44/118 52 (44–60)
Surgery CME 248/578 57 (53–61) 0.218 165/318 51 (45–56) 83/260 57 (53–61) 0.765
IME 91/188 52 (45–59) 58/101 46 (36–55) 33/87 52 (45–59)
Status Prior HDT
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Table 2. Cont.
CR 116/290 60 (54–66) 0.089 80/174 56 (48–63) 36/116 60 (54–66) 0.522
VGPR 140/308 55 (49–61) 86/159 50 (42–58) 54/149 55 (49–61)
PR 92/188 52 (45–59) 65/108 44 (34–53) 27/80 52 (45–59)
HDT BUMEL 238/605 60 (56–64) <0.001 121/257 56 (50–62) 117/348 60 (56–64) 0.267
CEM 134/239 46 (40–53) 124/209 44 (37–50) 10/30 46 (40–53)
Characteristics Total Population Control Group Immunotherapy Group p–value B
(B) Overall Survival Events/ Pts 5-year OS (95% CI) p-value A Events/Pts 5-year OS (95% CI) Events/Pts 5-year OS (95% CI)
Status Prior Maintenance
CR 190/468 60 (55–65) 0.006 129/258 54 (47–59) 61/210 60 (55–65) 0.640
VGPR 83/192 57 (49–64) 47/93 52 (42–62) 36/99 57 (49–64)
PR 61/109 43 (33–53) 38/57 36 (23–48) 23/52 50 (33–65)
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In the IP, the two-year and five-year EFS rates for 210 patients (81 events) in complete remission
(CR) were 68% (95% CI: 61–74%) and 61% (95% CI: 53–57%). In the CP, the two-year and five-year EFS
rates for 258 patients in CR (144 events) were 54% (95% CI: 48–60%) and 46% (95% CI: 39–52%).
The impact of immunotherapy on EFS was significantly influenced by stage and MC, and the
impact of immunotherapy was stronger in patients with metastatic disease (Table 2). Furthermore, a
borderline significant interaction between maintenance treatment and HDT (p = 0.055) was observed.
2.4. Multivariate Analysis on Analysis Cohort
Patients who had no immunotherapy (p = <.0001, cumulative hazard ratio (cHR) 1.75) HDT with
CEM (p = 0.0345, cHR 1.3); partial remission (PR) prior maintenance therapy (p = 0.0103, cHR 1.49);
more than one MC at diagnosis (p < 0.001, cHR 2.69) and age > 5 years (p = 0.0138, cHR 1.59) had a
higher risk of relapse (Table 3).
Table 3. Multivariate analysis of the analysis cohort. cHR (cumulative hazard ratios); 95% CI
(95% confidence interval); p-value (probability value); MNA (MYCN amplification); MC (metastatic
compartments, referring either to bone marrow, skeletal or lymph node involvement); TVD (topotecan,
vincristine and doxorubicin); CR (complete remission); VGPR (very good partial remission); PR
(partial remission); HDT (high-dose chemotherapy); BuMel (high-dose chemotherapy with busulfan
and melphalan); CEM (high-dose chemotherapy with carboplatin, etoposide and melphalan); IP
(immunotherapy population) and CP (control population). * test for the global main effect for
risk-factors with more than two categories.
Risk Factor Characteristics
Pseudo Values for 5-Years EFS
cHR (95% CI) p-Value
(A) Multivariate Analysis
Immunotherapy vs. Control Cohort 1.75 (1.36–2.25) <0.0001
Age (vs. <1.5 yrs) 0.0931 *
1.5–5 years 1.31 (0.92–1.87) 0.1384
>5years 1.59 (1.05–2.42) 0.0138
Stage 4, 4s and Number of MC (vs.
MNA stages 2, 3) <0.0001 *
1 MC 1.38 (0.80–2.47) 0.2493
>1MC 2.69 (1.74–4.15) <0.0001
TVD 1.28 (0.97–1.69) 0.2478
Status Prior Maintenance (vs. CR) 0.0363 *
VGPR 1.06 (0.81–1.39) 0.6416
PR 1.49 (1.10–2.02) 0.0103
HDT CEM vs. BuMel 1.32 (1.02–1.70) 0.0345
(B) Subgroup Analysis According to HDT(after adjustment for age, stage, MC, TVDand status prior maintenance treatment)
BUMEL IP vs. CP 1.6 (1.2–2.1) 0.001
CEM IP vs. CP 3.0 (1.5–5.8) 0.002
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After adjustment for age, stage, MC, TVD and response prior to maintenance therapy (Table 3),
a benefit from immunotherapy was confirmed for either HDT (busulfan and melphalan (BuMel) or
CEM). Patients receiving BuMel had an adjusted cumulative hazard ratio of 1.6 (1.2–2.1) with an
unadjusted five-year EFS for the IP of 56% (95% CI: 50–61%) and 48% (95% CI: 41–54%) for the CP
(p = 0.001). Patients receiving CEM had an adjusted cumulative hazard ratio of 3.0 (1.5–5.8) and showed
an unadjusted five-year EFS of the IP of 67% (95% CI: 47–80%) versus 35% (95% CI: 29–42%) for the CP
(p = 0.002).
2.5. Response to Maintenance Treatments
Thirty-nine of one hundred and eight (36%) CP patients with evaluable diseases prior to
maintenance (67 very good partial remission (VGPR) and 41 partial remission (PR)) responded;
of whom, 35/108 (32%) achieved CR after isotretinoin. In contrast, 64/130 (49%) of IP patients with
evaluable diseases (85 VGPR and 45 PR) prior to immunotherapy responded; of whom, 52/130 (40%)
achieved CR after immunotherapy (Table 4, p = 0.226).
Table 4. Response for immunotherapy and control populations. Legend: CR (complete
remission), VGPR (very good partial remission), PR (partial remission), SD (stable disease) and
PD (progressing disease).
Response Status before Maintenance Response Status after Maintenance
Total Evaluable CR VGPR PR SD PD
Immunotherapy and Isotretinoin
CR 210 188 151 0 0 0 37
<CR Total 151 130 52 43 8 0 27
VGPR 99 85 36 31 0 0 18
PR 52 45 16 12 8 0 9
Isotretinoin
CR 258 204 163 0 0 0 40
<CR Total 150 108 35 27 18 1 27
VGPR 93 67 28 23 2 0 14
PR 57 41 7 4 16 1 13
2.6. Adverse Events and Toxicity
Adverse events (CTC Grades 1 to 4) are summarized in Table 5. Toxicity tended to be higher in the
IP population, particularly in those patients who received sc-IL-2. Four patients had non-relapse-related
mortality in the IP and four in the CP.
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Table 5. Toxicities IL-2 (interleukin 2), non-hem. tox. (non-hematological toxicities), WBC (white blood cells), ECHO LV (left ventricular)/SV
(stroke volume), GFR (glomerular filtration rate), central neuro (central neurotoxicity), periph neuro (peripheral neurotoxicity) and liver enzymes: SGOT
(serum-glutamat-oxalacetat-transaminase)/SGPT (serum-glutamat-pyruvat-transaminase). Columns in bold show the values for the combined grade 3 and 4 toxicities.
Toxicities Control Without IL2 With IL2
Eval All All
0 1 2 3 4 3 + 4 0 1 2 3 4 3 + 4 0 1 2 3 4 3 + 4
Non-Hem. Tox. 317 113 42 116 41 5 46 15% 186 5 6 53 105 17 122 66% 192 4 2 20 113 53 166 86%
General Condition 314 225 69 13 4 3 7 2% 185 42 70 43 24 6 30 16% 192 25 53 36 66 12 78 41%
Haemoglobin 313 208 39 54 8 4 12 4% 186 21 2 84 69 10 79 42% 191 14 5 46 102 24 126 66%
WBC 313 235 32 28 15 3 18 6% 186 35 30 73 42 6 48 26% 191 35 30 57 51 18 69 36%
Granulocytes 313 244 23 25 16 5 21 7% 186 44 26 54 43 19 62 33% 191 34 12 34 69 42 111 58%
Platelets 313 260 13 12 16 12 28 9% 186 66 25 31 40 24 64 34% 191 30 18 26 61 56 117 61%
Infection 315 220 52 23 19 1 20 6% 185 79 26 32 47 1 48 26% 191 60 20 47 58 6 64 34%
Fever 314 241 14 54 4 1 5 2% 185 41 3 116 24 1 25 14% 190 28 4 82 66 10 76 40%
Stomatitis 312 293 10 7 2 0 2 1% 185 156 18 8 0 3 3 2% 191 149 27 12 2 1 3 2%
Nausea/Vomiting 313 284 6 19 4 0 4 1% 185 88 11 76 9 1 10 5% 191 68 12 94 14 3 17 9%
Diarrhoea 313 286 11 13 3 0 3 1% 185 93 32 47 10 3 13 7% 192 75 25 51 34 7 41 21%
Constipation 312 302 7 3 0 0 0 0% 185 110 43 32 0 0 0 0% 191 142 21 21 4 3 7 4%
Skin 315 181 50 73 10 1 11 3% 185 65 46 65 9 0 9 5% 192 48 48 77 19 0 19 10%
Allergy 314 307 4 3 0 0 0 0% 185 88 50 28 14 5 19 10% 191 75 39 38 32 7 39 20%
Cardiac Function 298 298 0 0 0 0 0 0% 182 178 0 0 3 1 4 2% 191 183 3 1 3 1 4 2%
Echo LV/SV 298 298 0 0 0 0 0 0% 182 181 0 0 0 1 1 1% 189 181 5 2 0 1 1 1%
Hypotension 298 296 2 0 0 0 0 0% 182 139 22 8 12 1 13 7% 191 119 23 17 25 7 32 17%
Hypertension 298 298 0 0 0 0 0 0% 182 162 10 3 7 0 7 4% 190 177 4 6 3 0 3 2%
Creatinine 312 301 9 2 0 0 0 0% 185 167 14 1 3 0 3 2% 192 159 20 11 2 0 2 1%
Proteinuria 311 307 4 0 0 0 0 0% 184 169 13 2 0 0 0 0% 191 178 12 1 0 0 0 0%
Haematuria 311 305 6 0 0 0 0 0% 183 167 11 5 0 0 0 0% 191 169 16 6 0 0 0 0%
GFR 310 302 5 3 0 0 0 0% 183 172 6 2 3 0 3 2% 190 179 9 1 1 0 1 1%
Central Neuro 311 304 4 0 0 3 3 1% 185 165 14 3 3 0 3 2% 191 158 16 6 3 8 11 6%
Periph Neuro 311 308 1 0 1 1 2 1% 185 173 8 3 1 0 1 1% 191 167 14 4 5 1 6 3%
Bilirubin 309 301 4 2 2 0 2 1% 185 169 1 10 4 1 5 3% 192 159 5 21 6 1 7 4%
SGOT/SGPT 311 218 68 19 6 0 6 2% 185 68 43 43 30 1 31 17% 192 68 40 40 43 1 44 23%
Dilated Pupils 22 22 0 0 0 0 0 0% 123 108 15 0 0 0 0 0% 125 95 30 0 0 0 0 0%
Accommodation Defects 22 22 0 0 0 0 0 0% 121 115 6 0 0 0 0 0% 125 111 14 0 0 0 0 0%
Capillary Leak Syndrome 19 18 0 1 0 0 0 0% 119 91 0 23 5 0 5 4% 124 70 0 35 16 3 19 15%
Cytokine Release Syndrome 19 18 1 0 0 0 0 0% 118 95 8 10 5 0 5 4% 123 85 12 17 9 0 9 7%
Pain related to ch14.18/CHO 122 42 17 44 19 0 19 16% 124 28 22 42 31 1 32 26%
Papilloedema 22 22 0 0 0 0 0 0% 120 113 7 0 0 0 0 0% 123 121 2 0 0 0 0 0%
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3. Discussion
This analysis showed superior EFS and OS in the era when dinutuximab beta-based
immunotherapy was included in therapy for high-risk neuroblastoma, compared to the previous era in
the same trial when isotretinoin alone was the only element of maintenance therapy. Although there
are limitations with a historical comparison, this is the first and possibly only demonstration that the
addition of dinutuximab beta as immunotherapy improves survival in the high-risk neuroblastoma
front-line population treated homogenously in the HR-NBL1/SIOPEN trial. Both the control and
immunotherapy populations received the same treatment approach. Furthermore, this analysis
is an important contribution, as data on the efficacy of anti-GD2 antibody-based immunotherapy
are limited to one prospective randomised trial and a few retrospective analyses. Ethical concerns
precluded a randomised comparison of immunotherapy after the results of the COG ANBL0032 trial
emerged. A randomised trial of dinutuximab beta and isotretinoin compared to isotretinoin alone
would have produced more robust data, but this was believed not to be ethically feasible within the
SIOPEN community.
As the two cohorts were from the same trial and using the same criteria; in particular, HDT
within nine months from diagnosis and no progression at 109 days after ASCR as a starting point for
survival, with an unchanged supportive care protocol guidance, this analysis provides important data
supporting the benefit of dinutuximab beta-based immunotherapy. The landmark time identified was
the median time observed between ASCR and initiation of dinutuximab beta; thus, only patients without
progressive diseases at this timepoint were included in the pre-immunotherapy CP. The introduction
of this landmark was important in order to exclude early relapse before immunotherapy could be
commenced. Both populations, IP and CP, were balanced for age, sex, stage 4, MYCN amplification
and response prior to HDT.
The benefit of immunotherapy was further underpinned by multivariate analysis. After adjustment
for risk factors (for example, age, stage, MC at diagnosis, need for TVD and response prior to
maintenance therapy) a positive impact on outcome was observed with either BuMel or CEM. This is
particularly important in view of a higher percentage of patients receiving CEM in the control group, as
we previously have shown superior outcomes for patients treated with BuMel [6]. Hence, the superior
outcomes in the immunotherapy group are unlikely to be solely related to BuMel. These conclusions
are supported by the recent publication from COG [13] demonstrating that immunotherapy improves
survival even after optimised HDT regimens.
Response prior to immunotherapy is an important prognostic factor. Patients treated in CR in the
IP had a two-year EFS of 68%, compared to 54% in the CP. Acknowledging that comparisons across
trials are challenging, these results are similar to the previous report of dinutuximab in combination
with IL-2 and GM-CSF in patients in CR, resulting in a two-year EFS of 66% for patients treated by
immunotherapy, compared to only 46% in patients with an isotretinoin maintenance treatment [7].
Further support in favour of dinutuximab beta-based immunotherapy within the HR-NBl1/SIOPEN
trial comes from improved response rates in patients with residual diseases at the site of the primary
tumour or metaiodobenzylguanidine (mIBG)-positive skeletal disease following immunotherapy;
a 49% response rate and a 40% CR rate was observed in patients treated with immunotherapy, as
compared to a 36% overall response and 32% CR rate in the control population.
The increasing role for immunotherapy, with anti-GD2 antibodies, in the therapy of patients with
high-risk neuroblastoma is further highlighted by the recent demonstration of the efficacy of combining
anti-GD2 antibodies with chemotherapy, either at relapse or at initial presentation [14,15].
In summary, this report describes the effects of including dinutuximab beta in high-risk
neuroblastoma maintenance therapy and shows a clear survival benefit. This provides an important
baseline to further build immunotherapy strategies in this challenging patient population.
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4. Materials and Methods
4.1. Trial Eligibility
HR-NBL1/SIOPEN, an international, randomised, multiarm, open-label, phase 3 trial for high–risk
neuroblastoma, opened on 24 June 2002 and is registered with ClinTrials.gov, number NCT01704716,
and EudraCT, number 2006-001489-17. All randomisations of the HR-NBL1/SIOPEN trial are closed,
and three have been published [5,6,12]. SIOPEN institutions recruited patients after approval of
the trial by national regulatory authorities and ethical committees. Parents/guardians and patients
provided written informed consent or assent, when applicable.
The International Neuroblastoma Staging System criteria (INSS) and International Neuroblastoma
Response Criteria (INRC) [16] were used to classify the disease and to evaluate responses to therapy.
Untreated patients with INSS stage 4 metastatic neuroblastoma aged 1-20 years or INSS stage 2–4
neuroblastoma with MYCN amplification, as determined in SIOPEN reference laboratories [17], any age
up to 20 years, were eligible. The SIOPEN-R-NET web-based system (https://www.siopen-r-net.org/)
randomly assigned eligible patients in real-time.
4.2. Eligibiliy for the Analysis Cohort and Treatments Given
This analysis included all patients registered in the HR-NBL1/SIOPEN trial between 2002 and
2013 who met the criteria: (i) HDT within 9 months from diagnosis and (ii) no progression at 109
days after ASCR. The median time between ASCR and initiation of dinutuximab beta was 109 days;
therefore, only patients without progressive diseases at this landmark timepoint were included in
the pre-immunotherapy control population (CP). The 18 patients randomised to receive dinutuximab
beta and isotretinoin between 2006 and 2009 were excluded from this analysis. Two cohorts were
compared, a CP between 2002–2009 who did not receive dinutuximab beta and an IP between 2009 and
2013 who was randomised to receive dinutuximab beta with or without sc-IL2 [12]. As the addition
of IL-2 to immunotherapy with dinutuximab beta did not improve outcome, both randomised arms
were considered as one group for the purposes of this analysis [12]. The CP comprised patients who
received HDT randomised to BuMel or CEM [6] but did not receive immunotherapy.
All patients received rapid COJEC induction [4,5] (Figure 4). Between 2002 to 2010, patients
who had a bone marrow complete response (CR) and a metastatic CR or a metastatic partial response
(PR) defined by INSS criteria but at least 50% reduction in skeletal metaiodobenzylguanidine (mIBG)
positivity from baseline and three or fewer areas of abnormal uptake on 123I-mIBG scintigraphy
were eligible for HDT randomisation comparing BuMel with CEM [6]. Thereafter, BuMel became
the standard of care. Patients who did not achieve a metastatic response to fulfil the HDT eligibility
criteria received two courses of topotecan, vincristine and doxorubicin (TVD) [18] prior to HDT. Local
treatment of the primary tumour comprised attempted total surgical resection and radiotherapy (21 Gy)
to the primary tumour site between 60 and 90 days after ASCR. There was no dose modification in the
event of incomplete tumour excision; neither were metastatic sites systematically irradiated.
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4.3.1. Establishment of the Analysis Cohort (Figure 1) 
The number of MC at diagnosis was calculated according to the number of MC at diagnosis 
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.
All patients received 6 cycles of oral isotretinoin over two weeks [3] after local irradiation. From
2009, patients were randomised between day 60 to 90 after ASCR to receive five courses of dinutuximab
beta at a dose of 20 mg/m2/day as an 8 infusion for 5 consecutive days (total dose of 100 mg/m2 per
cycle, days 8 to 12) with or without 6 × 106IU/m2/day of sc-IL-2 on days 1 to 5 and days 8 to 12 of each
immunotherapy cycle [12].
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Patients had full disease evaluations prior to and after 2 and 5 courses of maintenance treatment.
This included whole body 123I-mIBG scintigraphy, CT or MRI scans of the primary tumour and any
other evaluable site of the disease; bone marrow examination with both aspirates and trephines
obtained from two sites and measurement of urinary catecholamine metabolites. Response was
assessed by the 1993 INRC based on local institution reporting. The only evaluable diseases prior to
immunotherapy were mIBG-positive skeletal disease or diseases detectable on CT/MRI scans prior to
randomisation, as patients with bone marrow involvement were not eligible.
4.3. Statistical Analysis
4.3.1. Establishment of the Analysis Cohort
The number of MC at diagnosis was calculated according to the number of MC at diagnosis either
in the bone marrow, skeleton or other sites, with a possible range from one to six. Characteristics of the
CP were compared to the IP by the chi-square test to assess the balance of risk factors between the
two populations.
4.3.2. Outcome Parameters
Follow-up commenced at 109 days for the CP cohort and from the first dose of dinutuximab beta
for the IP cohort. EFS and OS were estimated using the Kaplan and Meier method and compared with
the log-rank test [19]. CIR was estimated [20], taking into account the competing risk of death without
relapse/progression. For cumulative incidence of non-relapse mortality, relapse or progression was
considered as a competing event. The statistical comparison of cumulative incidences used Gray’s
methodology [21]. EFS, OS, cumulative incidence of relapse/progression and cumulative incidence
of non-relapse mortality are presented as 5-year point estimates with confidence intervals (CI), as
previously described [20,22]. Two-year EFS was determined to facilitate comparisons with published
data [7]. p-values of less than 0.05 were considered to indicate statistical significance. In spite of the
limitations of subgroup analysis (including multiple testing and lack of power), the cohorts were
assessed according to baseline, pre and post-HDT risk factors (Table 2). A formal test for interaction
was performed within a Cox model.
4.3.3. Multivariate Analysis
Multivariate analysis of treatment and risk factors was undertaken on the analysis cohort. In the
presence of nonproportional hazards, as detected for age and MYCN amplification, the pseudo-value
regression [22] for a 5-year EFS approach was chosen. The aim of this analysis was to adjust the
comparison between the two populations (IP and CP) for potential confounders and risk factors,
such as age, stage, addition of TVD, disease status prior to maintenance and HDT/ASCR. Using the
same approach, a subgroup analysis was performed in order to separately evaluate the value of
immunotherapy in patients with BuMel and CEM.
The data cut-off time of this analysis was July 31, 2017. Median follow-up was calculated using
the inverse Kaplan Meier estimate. The statistical evaluation and power calculation were done with
SAS 9.4 and Module LR1 of Pass 2002, respectively.
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5. Conclusions
This report shows that the introduction of dinutuximab beta is associated with a survival benefit
for children with high-risk neuroblastoma. Similar results were reported for dinutuximab in one
randomized trial and one nonrandomized investigation [23–25]. However, dinutuximab beta is a
different molecule with a separate development pathway, and the demonstration of its beneficial effects
on treatment outcome is an important finding.
Given the absence of a beneficial effect by adding sc-IL-2 to an 8 h infusion of dinutuximab
beta [12], the standard treatment recommended by SIOPEN is dinutuximab beta with isotretinoin for
maintenance therapy of high-risk neuroblastoma. The benefits might be less in some subgroups (<1.5
years, MYCN-amplified localised disease) and needs close monitoring in future studies. Modifications
of the length of the dinutuximab beta schedule and immunotherapy combination strategies may
optimise the benefits of immunotherapy in high-risk neuroblastoma to improve survival.
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